生物技术公司 Upstream Bio 将其 IPO 定价为 $17/股，每股 15M 股，目标是 $255M，verekitug 的目标是 COPD。 Upstream Bio, a biotech firm, prices its IPO at $17/share for 15M shares, aiming for $255M, with verekitug targeting COPD.
一家专注于炎症疾病的生物技术公司Upstream Bio已将其首次公开募股 (IPO) 定价为每股17美元,价格为1500万股,目标是获得2.55亿美元的毛利. Upstream Bio, a biotech firm focused on inflammatory diseases, has priced its initial public offering (IPO) at $17 per share for 15 million shares, aiming for $255 million in gross proceeds. 股票将于2024年10月11日在纳斯达克上市,标签为"UPB". Shares will debut on the Nasdaq under the ticker "UPB" on October 11, 2024. 该公司正在研制Verekitug,这是一种单克隆抗体,针对关键的发炎性细胞外皮,计划对慢性阻塞性肺病进行试验。 The company is developing verekitug, a monoclonal antibody targeting a key inflammatory cytokine, with plans to pursue trials for chronic obstructive pulmonary disease.